{"entity":{"id":"leucid-bio","kind":"company","name":"Leucid Bio","aka":[],"tldr":"Leucid Bio is a London company, spun out of King's College London, that re-engineers CAR-T cells, a patient's own immune cells modified to find cancer, so that they work against solid tumours. Its first product, LEU011, is in an early trial.","summary":"Leucid Bio, headquartered in London with operations at Guy's Hospital, was founded in 2014, according to the company, to translate CAR-T research led by John Maher at King's College London. Its Lateral CAR platform redesigns the receptor so that signalling domains are distributed laterally, as in natural immune receptors. The lead product LEU011 is an NKG2D-targeting lateral CAR-T therapy given as a single intravenous dose after preconditioning chemotherapy, and the company is also developing an in vivo programme with Syenex. It raised GBP 11.5 million in a Series A in 2021, and names Epidarex, 2Invest, Sofinnova Partners, Vulpes Investment Management and the Future Fund of the British Business Bank as investors. Its first registered cancer trial, NCT06193902 (AERIAL), a phase 1/2a dose-escalation study of LEU011 in relapsed or refractory solid tumours in London and Manchester, was posted on ClinicalTrials.gov in January 2024; the registry gives its start as November 2023.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://www.leucid.com/"},{"label":"About Leucid Bio","url":"https://www.leucid.com/about"},{"label":"ClinicalTrials.gov: AERIAL phase 1/2a trial of LEU011 (NCT06193902)","url":"https://clinicaltrials.gov/study/NCT06193902"}],"tags":[],"related":[],"cancers":[],"sections":["cell-therapy","immunotherapy"],"technologies":["car-t"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06193902"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["NKG2D is named in the company's AERIAL announcement headline; no NKG2D target record exists in the corpus, so targets is left empty. Read on 29 October 2026."],"hq":"London","country":"GB","companyType":"cell-therapy","website":"https://www.leucid.com/","founded":2014,"stage":"startup","investors":["sofinnova-partners"],"funding":[{"round":"Series A","year":2021,"source":"https://www.leucid.com/about","note":"GBP 11.5 million, as stated on the company website"}]},"route":"/companies/leucid-bio/","neighbours":{"section":[{"id":"cell-therapy","kind":"section","name":"Cell Therapy","route":"/fronts/cell-therapy/"},{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"technology":[{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/"}],"trial":[{"id":"nct06193902","kind":"trial","name":"LEU01101: Safety and Preliminary Efficacy of LEU011 in Solid Tumours.","route":"/trials/nct06193902/"}],"company":[{"id":"sofinnova-partners","kind":"company","name":"Sofinnova Partners","route":"/companies/sofinnova-partners/"}]}}